Parabilis Medicines is a clinical-stage biopharmaceutical company founded in 2015. It is developing a new class of alpha-helical peptides, branded Helicons™, designed to target intracellular protein-protein interactions that have historically been considered 'undruggable'. The company's work focuses on cancer and other diseases.
The company's proprietary Helicons™ platform produces peptides engineered to access and modulate these challenging intracellular targets. Its lead investigational medicine, zolucatetide (FOG-001), is described as the first and only direct inhibitor of the β-catenin:TCF interaction, a key pathway in certain cancers.
Parabilis Medicines has raised over $305 million in funding to support its research and development programs. Its technical domains include peptide engineering, drug development, oncology, and protein-protein interaction modulation.
